Pharmafile Logo

Piramal | Healthcare

Pharma Solutions is the contract development and manufacturing (CDMO) division of Piramal | Healthcare, a part of the Piramal Enterprise. We are one of the largest custom manufacturing companies in the world that provides flexibility and scalability of operations. We have created a vast network of contract development and manufacturing facilities located in North America, Europe and Asia that offers a multitude of services that cover the entire drug-cycle, from development and commercial manufacturing to off-patent supplies of Active Pharmaceutical Ingredients (APIs) and formulations. Our network enables us to deliver benefits by strategically placing projects to take advantage of low costs, local supply chains and specific customer/ market requirements. This division features among the top 10 contract drug manufacturers in the world.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

247 Business Park, A - Wing, 6th Floor, LBS Marg, Vikhroli (West), Mumbai, Maharashtra, 400083, India
022-30956893

 Latest Content from PMHub 

Pegasus Moves to Brighton

Press Releases | April 29, 2014 | Inizio

Top UK Healthcare Communications Consultancy Moves to Brighton

UX: Designing Human Experiences

Applying science to the creative process to improve lives

08 UX: Pushing the right buttons

Unlocking better outcomes in healthcare with UX

UX: Pushing the right buttons

Unlocking better outcomes in healthcare with UX

07 Good Pharma

Better for patients, better for business

05 Social Media: A Health Hazard?

The case to embrace going social

Creating a Lifeline to the New Digital User

Today, we’re focussed on getting to know our new target: she’s online, mobile, and connected to a large network of friends, information, and marketers who help her make decisions about...

Warehousing of HCV patients reaches new high

White Papers and Resources | December 19, 2013 | Inizio

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

White Papers and Resources | December 19, 2013 | Inizio

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.